866-997-4948(US-Canada Toll Free)

Hepatic (Liver) Metastasis - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Dec 2013

Category :

Oncology

No. of Pages : 77 Pages


Global Markets Directs, \'Hepatic (Liver) Metastasis Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Hepatic (Liver) Metastasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatic (Liver) Metastasis. Hepatic (Liver) Metastasis Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Hepatic (Liver) Metastasis.
  • A review of the Hepatic (Liver) Metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Hepatic (Liver) Metastasis pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Hepatic (Liver) Metastasis.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Hepatic (Liver) Metastasis pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Hepatic (Liver) Metastasis Overview 8
Therapeutics Development 9
Pipeline Products for Hepatic (Liver) Metastasis - Overview 9
Pipeline Products for Hepatic (Liver) Metastasis - Comparative Analysis 10
Hepatic (Liver) Metastasis - Therapeutics under Development by Companies 11
Hepatic (Liver) Metastasis - Therapeutics under Investigation by Universities/Institutes 12
Hepatic (Liver) Metastasis - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Hepatic (Liver) Metastasis - Products under Development by Companies 16
Hepatic (Liver) Metastasis - Products under Investigation by Universities/Institutes 17
Hepatic (Liver) Metastasis - Companies Involved in Therapeutics Development 18
Novartis AG 18
Cleveland BioLabs, Inc. 19
CytRx Corporation 20
S.L.A. Pharma AG 21
Incuron, LLC 22
Gradalis Inc. 23
TARGETOME 24
Hepatic (Liver) Metastasis - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Combination Products 26
Assessment by Target 27
Assessment by Mechanism of Action 30
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Assessment by Therapeutic Class 37
Drug Profiles 40
icosapent - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
FANG Vaccine - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
177Lu-DOTA-TATE - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
pasireotide - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
entolimod - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Curcumin C3-Complex + [fluorouracil] + [oxaliplatin] + [leucovorin calcium] - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
mepacrine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
disulfiram + [copper gluconate] - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Salmonella typhimurium - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Anti-CEA Designer T Cells - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Antibody Against FERM Domain-Containing Protein 4A - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Cyt-HiPoA - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
TGM-001 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
TGM-002 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
TGM-003 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Fv-p53 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
TGM-004 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
TGM-005 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Hepatic (Liver) Metastasis - Recent Pipeline Updates 63
Hepatic (Liver) Metastasis - Dormant Projects 73
Hepatic (Liver) Metastasis - Product Development Milestones 74
Featured News & Press Releases 74
May 01, 2013: Cleveland BioLabs And Roswell Park Announce Publication Of Studies Defining Role Of Liver In Activity Of Entolimod 74

Appendix 76
Methodology 76
Coverage 76
Secondary Research 76
Primary Research 76
Expert Panel Validation 76
Contact Us 77
Disclaimer 77

List of Table


Number of Products under Development for Hepatic (Liver) Metastasis, H2 2013 9
Number of Products under Development for Hepatic (Liver) Metastasis - Comparative Analysis, H2 2013 10
Number of Products under Development by Companies, H2 2013 11
Number of Products under Investigation by Universities/Institutes, H2 2013 13
Comparative Analysis by Clinical Stage Development, H2 2013 14
Comparative Analysis by Early Stage Development, H2 2013 15
Products under Development by Companies, H2 2013 16
Products under Investigation by Universities/Institutes, H2 2013 17
Hepatic (Liver) Metastasis - Pipeline by Novartis AG, H2 2013 18
Hepatic (Liver) Metastasis - Pipeline by Cleveland BioLabs, Inc., H2 2013 19
Hepatic (Liver) Metastasis - Pipeline by CytRx Corporation, H2 2013 20
Hepatic (Liver) Metastasis - Pipeline by S.L.A. Pharma AG, H2 2013 21
Hepatic (Liver) Metastasis - Pipeline by Incuron, LLC, H2 2013 22
Hepatic (Liver) Metastasis - Pipeline by Gradalis Inc., H2 2013 23
Hepatic (Liver) Metastasis - Pipeline by TARGETOME, H2 2013 24
Assessment by Monotherapy Products, H2 2013 25
Assessment by Combination Products, H2 2013 26
Number of Products by Stage and Target, H2 2013 29
Number of Products by Stage and Mechanism of Action, H2 2013 32
Number of Products by Stage and Route of Administration, H2 2013 34
Number of Products by Stage and Molecule Type, H2 2013 36
Number of Products by Stage and Therapeutic Class, H2 2013 39
Hepatic (Liver) Metastasis Therapeutics - Recent Pipeline Updates, H2 2013 63
Hepatic (Liver) Metastasis - Dormant Projects, H2 2013 73

List of Chart


Number of Products under Development for Hepatic (Liver) Metastasis, H2 2013 9
Number of Products under Development for Hepatic (Liver) Metastasis - Comparative Analysis, H2 2013 10
Number of Products under Development by Companies, H2 2013 11
Number of Products under Investigation by Universities/Institutes, H2 2013 12
Comparative Analysis by Clinical Stage Development, H2 2013 14
Comparative Analysis by Early Stage Products, H2 2013 15
Assessment by Monotherapy Products, H2 2013 25
Number of Products by Top 10 Target, H2 2013 27
Number of Products by Stage and Top 10 Target, H2 2013 28
Number of Products by Top 10 Mechanism of Action, H2 2013 30
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 31
Number of Products by Top 10 Route of Administration, H2 2013 33
Number of Products by Stage and Top 10 Route of Administration, H2 2013 34
Number of Products by Top 10 Molecule Type, H2 2013 35
Number of Products by Stage and Top 10 Molecule Type, H2 2013 36
Number of Products by Top 10 Therapeutic Class, H2 2013 37
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 38

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *